COLLIGO-HCM
-
Bristol Myers Squibb Presents Real-World Camzyos (mavacamten) Outcomes Across Four Continents at ESC Congress 2025
The COLLIGO-HCM study, part of the WAYFARER-HCM program, presented at ESC Congress 2025, demonstrates Camzyos’ efficacy and safety in treating obstructive hypertrophic cardiomyopathy (oHCM). Real-world data showed significant reduction in left ventricular outflow tract (LVOT) obstruction and symptom alleviation in a diverse patient population, aligning with previous clinical trials. Nearly 60% of patients improved NYHA class by week 24 and the benefits were sustained through 96 weeks. The study also suggests Camzyos allows for reduced use of other medications.
